Comparative Pharmacology
Head-to-head clinical analysis: DISPERMOX versus LAROTID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DISPERMOX versus LAROTID.
DISPERMOX vs LAROTID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and disrupting peptidoglycan cross-linking.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
Adults: 1 g (as amoxicillin 875 mg + clavulanate 125 mg) orally every 12 hours for 7-10 days.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
None Documented
None Documented
Terminal elimination half-life 1.5 hours; prolonged in renal impairment.
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
Renal excretion 80% as unchanged drug, biliary/fecal 10%.
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic